Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast Cancer

Abstract

A panel of five antibodies can significantly improve on traditional prognosticators in predicting outcome for ER-positive breast cancer patients.

A novel five-antibody immunohistochemical test for subclassification of lung carcinoma

“…27 For each antibody, dilutions were first tested on a small 'titer' tissue array that had lung cancer cases with positive and negative cases for all antibodies in the panel, in addition to a set of tumor-derived cell lines suspended in paraffin. For the training cohort (CCIH), commercially available antibodies used in the discovery of the minimal antibody set (ER, PR, EGFR, ERBB2, KIT, CK5/6, CK17, TP53, and KI67) slides were stained by a commercial service (US Labs Inc., CA, USA).…”

Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas

“…The Mammostrat immunohistochemical assay (Clarient, Aliso Viejo, CA, USA), based on the assumption that gene expression can be translated into protein expression data, 10 measures the expression of SLC7A5, involved in nutrient transport; p53, involved in cell cycle checkpoint control; HTF9C, a gene whose expression oscillates during the cell cycle; NDRG1, a stress-and hypoxiainducible gene; and CEACAM5, a carcinoembryonic differentiation antigen. [10][11][12] Based on the expression of these proteins a Prognostic Index is calculated and patients are classified into three risk categories as well: low (r0), moderate (40 and r0.7) and high (40.7) risk of recurrence.…”

“…[10][11][12] Based on the expression of these proteins a Prognostic Index is calculated and patients are classified into three risk categories as well: low (r0), moderate (40 and r0.7) and high (40.7) risk of recurrence.…”

“…Although both the Oncotype DX Recurrence Score 3,13,14 and the Mammostrat Prognostic Index [10][11][12] have been validated in multiple studies, and the Recurrence Score has been incorporated into clinical guidelines for management of breast cancer, 15,16 several questions remain unanswered. Although both were validated in the same cohorts of patients (NSABP B14 and B20), they have not been compared head-to-head and little data are available regarding their correlation with clinicopathologic tumor features.…”

“…The Mammostrat assays were performed and analyzed by Clarient as previously described. [10][11][12] A double immunohistochemical stain for pancytokeratin and Ki-67 was performed in each case to assess cell proliferation in cancer vs stromal/inflammatory cells, as previously described. 19 The areas of cancers showing the highest numbers of Ki-67-positive cancer and stromal/inflammatory cells were identified at lowpower magnification.…”